Our Total Myeloma Care Treatment Approach

Here at NCIS, we adopt a comprehensive and holistic three-prong Total Myeloma Care approach in managing patients who have been afflicted with Multiple Myeloma.


Under the Total Myeloma Care approach, emphasis is centered on the patient with clinical, research and educational initiatives focused on them. Current treatment is optimized, value-added resources are provided and there is increased access to new drugs to counter patient’s relapse.


Furthermore, continuous research is conducted to seek out new treatments alongside patient education to guide patients through their journey with Multiple Myeloma. 


Optimising Clinical Care

Multiple Myeloma is considered a very heterogenous disease with varying patient survival rates despite receiving the same level of treatment. It is therefore crucial to identify characteristics of patients with different clinical behaviours to administer the suitable treatment process.


At NCIS, through a risk stratified approach targeted separately at high-risk and low-risk patients, we are able to not only significantly improve the treatment outcome for patients afflicted with Multiple Myeloma, but allow our patients to derive maximum benefits from prescribed medications.


Typically, for younger patients diagnosed with Multiple Myeloma, they are required to be warded in an isolation room for three weeks or so. However, at NCIS, we utilise a transplant procedure whereby patients are able to undergo chemotherapy and stem cell infusion in our cancer centre but discharged to be cared for in the comfort of their own homes. The patient and his/her family are extensively educated and prepared on the necessary precautions to take at home with the patient only having to return to the clinic for periodic reviews when necessary.


Typically, patients diagnosed with high-risk Multiple Myeloma only have a survival time of less than two years, even with the best possible treatment. Thus, at NCIS, we focus our research towards understanding the nature of these high-risk diseases and developing therapeutics effective in countering these tumours to prolong the lifespan and quality of lives of those who have been afflicted with the illness.


On the management front, as there is always a therapeutic risk of drug resistance and potential relapse, we have also undertaken several research initiatives to zoom into the molecular characteristics of these resistant cells in order to fully eradicate them.


Patient Education and Support

At NCIS, we understand that patients afflicted with Multiple Myeloma often feel isolated and confused by the different treatment options available to them, as well as feel overwhelmed by the hefty treatment costs.

To provide our patients with a relatable support system to ease them through their journey with the illness, we offer the following support services and functions:

  • A Navigator – To act as a contact point and pillar of support to our patients by assisting with the coordination of their medical appointments etc. 
  • Patient Support Groups – To embrace patients into a larger support community of like-minded individuals who are there to listen and share their experiences in dealing with the illness.
  • Interactive Website – Providing patients with accessible and convenient access to expert and up-to-date information pertaining to the illness as well as providing patients with a platform to blog about their personal experiences and make online enquiries with our doctors about their symptoms.

Back to Top